Sold as Valpin 50. Every FDA application for this active ingredient: 1 branded and 1 generic.
As of Nov 16, 2026, FDA lists 2 applications for Anisotropine Methylbromide (sold as Valpin 50), first approved Nov 23, 1962, with 1 new use approved and 0 published complete response letters.
| Nov 23, 1962 | Valpin 50NDA 13428 · New dosage form | Endo Pharms | 8 | Discontinued |
| — | Anisotropine MethylbromideANDA 86046 | Watson Labs | 1 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA